Global Osteoarthritis Therapeutics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Osteoarthritis Therapeutics Market Size

• The global osteoarthritis therapeutics market size was valued at USD 8.67 billion in 2024 and is expected to reach USD 17.29 billion by 2032, at a CAGR of 9.00% during the forecast period
• The market growth is largely fueled by the increasing prevalence of osteoarthritis worldwide, particularly among the aging population, combined with advances in therapeutic development including biologics, cell-based therapies, and disease-modifying osteoarthritis drugs (DMOADs). This trend is driving greater focus on early diagnosis and personalized treatment approaches
• Furthermore, rising patient awareness, improved access to healthcare in emerging markets, and increasing demand for minimally invasive and long-acting treatment options are positioning osteoarthritis therapeutics as a critical component of musculoskeletal care. These converging factors are accelerating the uptake of Osteoarthritis Therapeutics solutions, thereby significantly boosting the industry's growth

Osteoarthritis Therapeutics Market Analysis

• Osteoarthritis therapeutics, including pharmacological agents, biologics, and intra-articular injections, are becoming increasingly vital components of musculoskeletal care in both primary and specialty healthcare settings due to their effectiveness in managing chronic joint pain, improving mobility, and delaying the need for surgical interventions
• The escalating demand for osteoarthritis therapeutics is primarily fueled by the aging global population, rising obesity rates, increasing awareness of joint health, and advancements in regenerative medicine and disease-modifying osteoarthritis drugs (DMOADs)
• North America dominated the osteoarthritis therapeutics market with the largest revenue share of 41.7% in 2024, driven by the high prevalence of osteoarthritis, strong healthcare infrastructure, favorable reimbursement policies, and the presence of major pharmaceutical companies investing in R&D for novel therapies. The U.S. continues to lead the region with widespread adoption of advanced treatment options such as platelet-rich plasma (PRP) injections and viscosupplementation
• Asia-Pacific is expected to be the fastest growing region in the osteoarthritis therapeutics market during the forecast period, with a CAGR of 9.6%, owing to rapidly aging populations, increasing healthcare spending, improving diagnosis rates, and a growing emphasis on non-surgical interventions across countries such as China, India, and Japan
• The viscosupplementation agents segment dominated the osteoarthritis therapeutics market with a market share of 34.5% in 2024, driven by their role in improving joint lubrication and delaying the need for surgical intervention. These agents are particularly effective in treating knee osteoarthritis and are widely adopted due to their minimal side effects

Report Scope and Osteoarthritis Therapeutics Market Segmentation

Osteoarthritis Therapeutics Market Trends

“Advancements in Targeted and Personalized Osteoarthritis Treatment Approaches”

• A significant and accelerating trend in the global osteoarthritis therapeutics market is the shift toward targeted biologics and personalized treatment regimens. Innovations in molecular diagnostics and genetic profiling are enabling clinicians to better understand patient-specific disease mechanisms and customize therapies accordingly
  • For instance, novel interleukin inhibitors and monoclonal antibodies are being developed and introduced to the market to target specific inflammatory pathways involved in osteoarthritis progression. These therapies aim not just to relieve symptoms but to halt or slow joint degeneration, offering hope for long-term relief and improved quality of life
• The integration of advanced imaging tools and biomarkers allows earlier diagnosis and helps physicians monitor disease progression more accurately, leading to better treatment outcomes. Companies are increasingly investing in companion diagnostics to pair with high-value osteoarthritis drugs, optimizing their effectiveness for distinct patient groups
• Increasing research on regenerative medicine, including stem cell therapy and tissue engineering, is offering new opportunities to restore damaged cartilage, moving beyond pain relief to actual structural repair. Several biotech startups and pharma companies are conducting clinical trials focused on intra-articular regenerative injections that promise fewer side effects and longer-lasting benefits
• The trend toward digital therapeutics and remote patient monitoring tools is also gaining traction, particularly for managing chronic pain and physical therapy adherence. Wearable devices and mobile health apps are helping track joint movement, exercise compliance, and treatment response—allowing for real-time care optimization
• This progression toward more personalized, regenerative, and data-driven treatment strategies is fundamentally reshaping patient expectations and clinical protocols. As a result, major players such as Pfizer, Novartis, Amgen, and Zimmer Biomet are accelerating their investments in targeted osteoarthritis therapies and digital health ecosystems to stay competitive in this evolving landscape

Osteoarthritis Therapeutics Market Dynamics

Driver

“Growing Need Due to Rising Disease Burden and Aging Population”

• The increasing global burden of osteoarthritis, particularly among the aging population, is a major driver fueling demand for effective osteoarthritis therapeutics. The World Health Organization reports that osteoarthritis is among the most disabling diseases in older adults, significantly affecting mobility and quality of life
  • For instance, in April 2024, AbbVie Inc. announced the expansion of its R&D program for osteoarthritis, focusing on next-generation anti-inflammatory biologics aimed at halting disease progression rather than just alleviating symptoms. Such strategic developments are expected to drive the osteoarthritis therapeutics industry growth in the forecast period
• As life expectancy increases worldwide, the prevalence of osteoarthritis is expected to rise proportionally. This shift is prompting healthcare systems to invest more heavily in disease management, while pharmaceutical companies focus on creating innovative and long-acting treatment options, including injectable hyaluronic acid, NSAIDs, and biologic therapies
• Moreover, the growing demand for pain management solutions, physical therapy integration, and joint-preserving drugs is making osteoarthritis treatment a priority area within rheumatology and orthopedics
• The convenience of oral, topical, and injectable treatment options, along with ongoing advancements in drug delivery systems and regenerative medicine, is improving patient compliance and expanding therapeutic applications across various care settings
• In addition, the rise in sedentary lifestyles and obesity is increasing the incidence of osteoarthritis among younger demographics, further contributing to market growth and creating new avenues for early intervention therapies and disease-modifying osteoarthritis drugs (DMOADs)

Restraint/Challenge

“High Development Costs and Limited Disease-Modifying Therapies”

• A significant challenge in the osteoarthritis therapeutics market is the limited availability of curative or disease-modifying treatments. Most current therapies are focused on symptom management, such as pain relief and inflammation control, rather than reversing or halting joint degeneration
  • For instance, while biologics and stem cell-based therapies show promise, they often face high development costs, extended clinical trial timelines, and complex regulatory pathways, which delay market entry and limit widespread accessibility
• Despite growing investment, few DMOADs have received regulatory approval, and the lack of long-term efficacy data remains a concern. This slows innovation and restricts treatment options for advanced-stage patients seeking alternatives to joint replacement surgery
• Moreover, the cost burden of advanced therapeutics—including biologics, PRP (platelet-rich plasma) injections, and customized implants—can be prohibitive for patients, especially in low- and middle-income regions where healthcare reimbursement is limited
• To overcome these barriers, industry players must focus on streamlining R&D, securing faster regulatory approvals, and developing cost-effective treatment alternatives that can deliver structural benefits alongside symptomatic relief
• Greater collaboration between public and private stakeholders, along with advancements in biomarker identification and early-stage diagnostics, will be essential for the development of breakthrough therapies that can transform the current treatment landscape

Osteoarthritis Therapeutics Market Scope

The market is segmented on the basis of drug type, anatomy, route of administration, sales channel, and end-use.

• By Drug Type

On the basis of drug type, the osteoarthritis therapeutics market is segmented into viscosupplementation agents, nonsteroidal anti-inflammatory drugs, analgesics, corticosteroids, and others. The viscosupplementation agents segment dominated the largest market revenue share of 34.5% in 2024, driven by their role in improving joint lubrication and delaying the need for surgical intervention. These agents are particularly effective in treating knee osteoarthritis and are widely adopted due to their minimal side effects.

The nonsteroidal anti-inflammatory drugs segment is anticipated to witness the fastest growth rate of 9.4% CAGR from 2025 to 2032, attributed to their widespread availability over the counter and increasing demand for pain relief medication. Their affordability and effectiveness for mild to moderate symptoms make them a preferred choice in both developed and developing regions.

• By Anatomy

On the basis of anatomy, the osteoarthritis therapeutics market is segmented into knee osteoarthritis, hip osteoarthritis, hand osteoarthritis, and others. The knee osteoarthritis segment accounted for the largest market revenue share of 47.8% in 2024, due to the high prevalence of knee joint degeneration among the elderly and obese populations. The knee is the most commonly affected joint, and treatment advancements continue to support strong market demand.

The hip osteoarthritis segment is expected to register the fastest CAGR of 8.7% from 2025 to 2032, fueled by increasing aging demographics and rising surgical interventions such as hip replacement procedures.

• By Route of Administration

On the basis of route of administration, the osteoarthritis therapeutics market is segmented into parenteral route, topical route and oral route. The oral route segment held the largest market revenue share of 51.3% in 2024, due to the high convenience and compliance among patients for tablets and capsules. Oral NSAIDs and analgesics are commonly prescribed as first-line treatments.

The parenteral route is anticipated to grow at the fastest CAGR of 9.1% from 2025 to 2032, driven by the increased use of intra-articular injections such as hyaluronic acid and corticosteroids, which provide targeted relief and longer-lasting effects.

• By Sales Channel

On the basis of sales channel, the osteoarthritis therapeutics market is segmented into prescription drugs and over-the-counter drugs. The prescription drugs segment dominated the market with a revenue share of 64.2% in 2024, attributed to physician-prescribed medications for moderate to severe cases and post-operative management.

The over-the-counter drugs segment is projected to grow at the fastest CAGR of 8.9% from 2025 to 2032, owing to the increasing trend of self-medication, rising awareness, and easy availability of NSAIDs and topical pain relief products in pharmacies and retail outlets.

• By End-use

On the basis of end-use, the osteoarthritis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share of 46.5% in 2024, driven by high patient flow in hospitals, access to advanced injectable treatments, and physician supervision.

The retail pharmacies segment is expected to witness the fastest CAGR of 9.3% from 2025 to 2032, fueled by the increasing availability of OTC medications, expanding pharmacy chains, and the preference for purchasing chronic medications from neighborhood drugstores.

Osteoarthritis Therapeutics Market Regional Analysis

• North America dominated the osteoarthritis therapeutics market with the largest revenue share of 41.7% in 2024, driven by the rising prevalence of osteoarthritis, increasing elderly population, and the widespread availability of advanced treatment options
• The region benefits from well-established healthcare infrastructure, high patient awareness, and strong reimbursement frameworks
• Patients in North America increasingly opt for viscosupplementation, NSAIDs, and corticosteroids, with growing adoption of novel therapies, including regenerative and biological approaches. Furthermore, the rise in obesity and sedentary lifestyles contributes significantly to osteoarthritis incidence, reinforcing the demand for effective therapeutic solutions

 U.S. Osteoarthritis Therapeutics Market Insight

The U.S. osteoarthritis therapeutics market captured the largest revenue share of 81% within North America in 2024, fueled by rapid uptake of innovative pharmacological therapies and the growing preference for personalized medicine. The U.S. leads in clinical trials, R&D investments, and approvals for next-generation therapies, supported by the presence of major pharmaceutical players. Moreover, the country’s aging population and increasing number of patients undergoing joint replacement surgeries have driven the demand for both symptomatic and disease-modifying treatments. The availability of over-the-counter pain relievers and strong physician recommendations further bolster the market.

 Europe Osteoarthritis Therapeutics Market Insight

The Europe osteoarthritis therapeutics market is projected to expand at a robust CAGR of 8.6% from 2025 to 2032, primarily driven by an aging demographic and rising awareness of early intervention strategies. Countries across Europe are seeing increasing uptake of topical and oral NSAIDs, along with viscosupplementation treatments. Public healthcare initiatives aimed at reducing disability caused by osteoarthritis, combined with supportive reimbursement policies, are promoting adoption. In addition, patient education and non-invasive therapies are gaining popularity across outpatient and homecare settings.

 U.K. Osteoarthritis Therapeutics Market Insight

The U.K. osteoarthritis therapeutics market is anticipated to grow at a CAGR of 8.9% from 2025 to 2032, driven by rising demand for non-surgical pain management and government focus on improving access to primary healthcare. The National Health Service (NHS) plays a pivotal role in delivering osteoarthritis care, often encouraging the use of analgesics and physical therapy in early stages. Growing emphasis on reducing joint replacement surgery burden is also increasing reliance on pharmacological therapeutics and early-stage interventions.

Germany Osteoarthritis Therapeutics Market Insight

The Germany osteoarthritis therapeutics market is expected to expand at a CAGR of 8.4% from 2025 to 2032, supported by increasing diagnosis rates and the adoption of biologic therapies for advanced cases. Germany's highly developed healthcare system and the availability of advanced intra-articular injections are driving market growth. In addition, rising awareness campaigns by healthcare organizations and patient support groups are promoting earlier treatment initiation and improved medication adherence.

Asia-Pacific Osteoarthritis Therapeutics Market Insight

The Asia-Pacific osteoarthritis therapeutics market is poised to grow at the fastest CAGR of 9.6% from 2025 to 2032, driven by a combination of aging populations, increasing joint disorders, and healthcare infrastructure development in emerging economies. Countries such as China, Japan, and India are witnessing increasing osteoarthritis diagnoses, with growing use of NSAIDs, corticosteroids, and hyaluronic acid injections. Government health programs and expanding pharmaceutical manufacturing capacities are making treatments more affordable and accessible to larger patient pools across the region.

 Japan Osteoarthritis Therapeutics Market Insight

The Japan osteoarthritis therapeutics market is gaining momentum, projected to grow at a CAGR of 10.3% from 2025 to 2032, owing to the country’s rapidly aging population and strong emphasis on geriatric care. Japanese patients favor minimally invasive treatments, including oral and topical NSAIDs. There is a significant push for innovation in cartilage regeneration and joint preservation techniques. Integration of traditional and modern medicine, as well as high per capita health expenditure, supports further market development.

China Osteoarthritis Therapeutics Market Insight

China accounted for the largest market revenue share in Asia Pacific in 2024, contributing 36.5% of the regional revenue, driven by its massive patient base, increasing healthcare access, and investments in domestic drug manufacturing. The market is witnessing a surge in demand for affordable oral and injectable therapies. Rising health awareness, government-led elder care policies, and rapid expansion of hospital infrastructure are accelerating therapeutic adoption. Local pharmaceutical companies are also increasingly active in the osteoarthritis drug pipeline and biosimilar development.

Osteoarthritis Therapeutics Market Share

The osteoarthritis therapeutics industry is primarily led by well-established companies, including:

• Pfizer Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Novartis AG (Switzerland)
• Amgen Inc. (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Samsung Bioepis (South Korea)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• AstraZeneca (U.K.)
• Zimmer Biomet (U.S.)
• Stryker (U.S.)
• Enlivex Therapeutics Ltd. (Israel)
• Anika Therapeutics, Inc. (U.S.)
• Eupraxia Pharmaceuticals (Canada)
• Doron Therapeutics (U.S.)

Latest Developments in Global Osteoarthritis Therapeutics Market

• In April 2024, Eli Lilly and Company announced the launch of a new monoclonal antibody therapy targeting nerve growth factor (NGF) to manage moderate to severe osteoarthritis pain. This innovative therapy, developed in collaboration with a leading biotechnology firm, aims to provide long-lasting pain relief without the adverse effects commonly associated with NSAIDs and opioids, positioning Lilly at the forefront of next-generation osteoarthritis treatment
• In March 2024, Pfizer Inc. initiated Phase III clinical trials for its investigational disease-modifying osteoarthritis drug (DMOAD), designed to slow cartilage degeneration in patients with knee osteoarthritis. This development aligns with the growing global focus on regenerative approaches and personalized medicine in chronic joint conditions
• In February 2024, Johnson & Johnson’s Janssen Pharmaceuticals division received FDA Fast Track designation for its small-molecule inhibitor aimed at halting osteoarthritis progression. The drug targets inflammatory pathways implicated in cartilage breakdown, marking a major advancement in modifying disease progression beyond symptomatic relief
• In January 2024, Sanofi and Regeneron expanded their collaboration to evaluate the potential of Dupilumab in treating osteoarthritis-related inflammation and pain. Preliminary studies demonstrated promising results in reducing joint stiffness and improving mobility, opening new therapeutic possibilities for patients unresponsive to traditional treatments
• In December 2023, GlaxoSmithKline (GSK) launched a novel topical analgesic gel incorporating nanotechnology for enhanced penetration and sustained pain relief. This product, developed for over-the-counter use, is tailored to improve the quality of life for patients with early-stage osteoarthritis and has seen strong market uptake across Europe and Asia-Pacific

SKU-54686